Oral Anticoagulant Therapy for Atrial Fibrillation Decreases Dementia Risk
A study was conducted to determine the effect of oral anticoagulant therapy on risk for dementia in patients with nonvalvular atrial fibrillation.
A study was conducted to determine the effect of oral anticoagulant therapy on risk for dementia in patients with nonvalvular atrial fibrillation.
Researchers sought to describe the prevalence of VHD stages among older adults; determine the prognostic relevance of VHD stages for incidence CVDs; and characterize the progression in VHD stages over 6 years in late life.
Researchers sought to compare quality of life outcomes between ablation and pharmacotherapy in women with atrial fibrillation.
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
Findings were consistent for patients aged 80 years or older and patients with chronic kidney disease, who are often underrepresented in clinical trials.
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
Researchers assessed the relationship between oral anticoagulation for patients with COVID-19 and AF and incidence of in-hospital thrombotic events and death.
A study was conducted to determine the efficacy of treating patients with ICDs and ventricular tachycardia with early catheter ablation.
A study was conducted to determine the epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices.
Landiolol is an ultra-short acting, cardioselective, beta-1 adrenoceptor blocker designed to reduce heart rate with a minimal effect over cardiac contractility.